July 9, 2002 Results of the Women’s Health Initiative (WHI), reported in the July 17 issue of The Journal of the American Medical Association, indicate that the combination of conjugated equine estrogen (0.625 mg/day) and medroxyprogesterone acetate (2.5 mg/day) (Prempro) is associated with an increased overall health risk.
Although the absolute risk was low, investigators stopped this arm of the study and suggested discontinuing this therapy.
“During one year, for every 10,000 women taking estrogen plus progestin, we would expect seven more women would have heart attacks (than in the placebo group), eight more women with strokes, eight more women with breast cancer, and 18 more women with blood clots,” investigator Denise E. Bonds, MD, MPH, from Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, says in a news release.
Despite the low absolute risk (2.5%) and the positive effect of six fewer cases of colorectal cancer and five fewer hip fractures per 10,000 women treated with Prempro, Bonds says that “the balance of risks significantly outweighed the benefits.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!